Evolving Biomarkers in Pancreatic Cancer: Path to PredictionNovember 14th 2021
According to Andrew S. Barbas, MD, of Duke Health, the scarcity of testing that can provide accurate results in patients with pancreatic cancer contributes to diagnoses in the advanced stages of the disease and consequently to poor prognoses.
Adding Camrelizumab to Chemotherapy Improves Survival in Patients With Advanced or Metastatic ESCCNovember 13th 2021
Results from the phase 3 ESCORT-1st trial have demonstrated promise for the combination of camrelizumab and chemotherapy in patients with advanced or metastatic esophageal squamous cell carcinoma.
Frontline Acalabrutinib Improves Quality-Adjusted Survival in CLLNovember 3rd 2021
Patients treated with acalabrutinib monotherapy had a significantly longer mean duration of time spent without toxicity compared with those treated with chlorambucil plus obinutuzumab in the phase 3 ELEVATE-TN trial.